NASDAQ · CMPS
COMPASS Pathways plc
$12.19-$0.09 (-0.73%)
COMPASS Pathways plc’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
Loading market information…
NYSE · EBS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Emergent BioSolutions Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Emergent BioSolutions Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$0.37. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Emergent BioSolutions Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | $0.71+44.9% vs estimate | $222.20M+1.46% vs estimate |
|---|
| Q4 2024 | Mar 3, 2025 | $0.05+114.29% vs estimate | $189.30M-32.15% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | $1.37+179.59% vs estimate | $293.80M+13.44% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $10.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$12.19-$0.09 (-0.73%)
COMPASS Pathways plc’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
$51.45+$0.71 (+1.4%)
Rigel Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.51% below the high.
$10.23-$0.29 (-2.76%)
Corvus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.04% below the high.
$3.18$0.00 (0.0%)
Esperion Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.83% below the high.
$7.33-$0.16 (-2.14%)
Olema Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.78% below the high.
$4.04-$0.19 (-4.49%)
Aquestive Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.7% below the high.
$8.88-$0.22 (-2.42%)
Prothena Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 24.75% below the high.
$1.30+$0.01 (+0.78%)
SNDL Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
